News

Rick Lewis, MD, Chief Medical Officer for ViaLase met with Ophthalmology Times to discuss completion of their important pivotal trial called VIA-002, which is a randomized prospective trial of the use of the ViaLase Laser versus SLT in adult patients with primary open angle glaucoma at the American Academy of Ophthalmology.

The week focuses on bringing awareness to TED through emphasis on mental health and art therapy solutions.

Penny Asbell, MD, FACS, spoke with Ophthalmology Times about her poster on results from the ARMOR Study and latest diagnostic and therapeutic advancements in ocular infections at this year's American Academy of Ophthalmology meeting.

Sean Hanlon, CEO of CoFi, spoke with Ophthalmology Times about company updates as well as their integration with CareCredit at this year's American Academy of Ophthalmology meeting.

Researchers found the growth of RPE cells was successfully controlled by the stencil patterns. When RPE cells were not held together correctly, the cells excreted levels of harmful proteins that could contribute to vision loss.

According to the company, OCU410ST uses an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene.

Clara Chan, MD, FRSCS, FACS, DABO, from the University of Toronto spoke with Ophthalmology Times about their study on the consistency of outcomes across 3 different cohorts of patients that were internationally collected at this year's American Academy of Ophthalmology meeting.

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Swarup Swaminathan, MD, spoke with Ophthalmology Times about using the Heidelberg SPECTRALIS and caring for our Glaucoma patients at this year's American Academy of Ophthalmology meeting.

Daniel Chang, MD, spoke with Ophthalmology Times about his poster "Clinical performance of a diffractive, extended depth-of-focus IOL, with violet light filtering and high-resolution lathing" at this year's American Academy of Ophthalmology meeting.

Researchers from Anglia Ruskin University and the University of Oxford conducted a study that reveals knowledge gaps for conditions that affect 18-64-year-olds in the UK.

NYU Langone Health performs landmark procedure called “major paradigm shift for potential vision therapies”

Megan Baldwin, MD, founder of Opthea Limited, spoke with Ophthalmology Times about the company's ShORe and COAST clinical trials at this year's American Academy of Ophthalmology meeting.

Rich Small, CEO of Neurotech, spoke with Ophthalmology Times about the company's development of encapsulated cell therapy, NT-501, at this year's American Academy of Ophthalmology meeting.

Nearly 75% of patients suffered eye infections following the event.

The study underscores the potential benefits of early detection of pathological changes in the retina and choroid before ocular symptoms manifest, particularly highlighting the promise of choroidal vascularity index as a robust evaluation tool.

Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

First-in-human feasibility study.

AMDX-2011P aims to revolutionize glaucoma detection with micron-level amyloid beta tracking.

The Women in Ophthalmology (WIO) survey by Johnson & Johnson Vision uncovers barriers faced by female ophthalmologists.

Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.

Ben Bergo, CEO of Visus Therapeutics spoke with Ophthalmology Times about the study on presbyopia, BRIO-I at this year's American Academy of Ophthalmology meeting.

Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America spoke with Ophthalmology Times about 3 new technologies the company launched at this year's American Academy of Ophthalmology meeting.

XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis.

ABP 938 is an investigational biosimilar to EYLEA® (aflibercept).

This retrospective, multicenter, observational study examined Japanese patients with GA to determine the clinical characteristics and GA progression rate associated with AMD in an Asian population.

Sterile corneal ulceration is a rare complication of rheumatoid arthritis and may lead to corneal perforation. However, surgeries performed to restore vision often are not successful.